| Young Investigator Session | 09:00~10:10 | ||
| Session 1 | Room A | ||
| 1) Exploring the role of miR-155 in breast cancer metabolism | |||
| Suhwan Chang (University of Ulsan College of Medicine) | |||
| 2) Novel therapeutic targets in multiple myeloma | |||
| Sun-Young Kong (National Cancer Center) | |||
| 3) Pre-existing secondary molecular alterations impact response to ERBB2-directed therapy in ERBB2-amplified gastric and esophageal adenocarcinoma | |||
| Jihun Kim (University of Ulsan College of Medicine) | |||
| Session 2 | Room C | ||
| 1) Bone marrow derived podoplanin+ cells can function as lymphatic endothelial progenitor cells | |||
| Ji Yoon Lee (The Catholic University of Korea) | |||
| 2) Digging the new targets in triple negative breast cancer | |||
| Joohyuk Sohn (Yonsei University College of Medicine) | |||
| 3) Tumor angiogenesis in gastric cancer | |||
| Do Joong Park (Seoul National University Bundang Hospital) | |||
| Plenary Lecture 1 | 10:30~11:10, Room A ~ C | ||
| Mutation profile and transriptomic analysis in lung adenocarcinoma, integrated with DNA methylation | |||
| Jeong-Sun Seo, M.D., Ph.D. (Seoul National University College of Medicine) | |||
| Plenary Lecture 2 | 11:10~12:00, Room A ~ C | ||
| RUNX and p53 function together to monitor the aberrant oncogenic activities | |||
| Yoshiaki Ito, M.D., Ph.D. (National University of Singapore, Singapore) | |||
| Symposium 1 | 13:20~15:10, Room A | ||
| Joint Symposium (Korean Cancer Association & Korean Genome Organization) | |||
| Discovery of cancer genome | |||
| 1) Analysis of large homozygous deletions of human gastric cancer cell lines by whole-genome and transcriptome sequencing | |||
| Seong-Jin Kim (CHA Cancer Institute, CHA University) | |||
| 2) Intratumoral heterogeneity of human cancers and the implication in clinical settings | |||
| Tae-Min Kim (The Catholic University of Korea College of Medicine) | |||
| 3) Development of efficient targeted gene capture technologies for cancer genomics | |||
| Duhee Bang (Yonsei University College of Science ) | |||
| 4) Systematic investigation of mutation effects on cancer genomes using next-generation sequencing: implication for current methods and future direction | |||
| Dongwan Hong (National Cancer Center) | |||
| Symposium 2 | 13:20~15:10, Room C | ||
| Tumor hypoxia | |||
| 1) Diverse roles of hypoxia-inducible factor (HIF) signaling in non-small cell lung cancer | |||
| Jung-whan Kim (The University of Texas at Dallas, USA) | |||
| 2) Hypoxic reprogramming in histone code by inhibiting the activities of histone demethylases | |||
| Hyunsung Park (University of Seoul College of Natural Science ) | |||
| 3) Silencing of tumor suppressors by epigenetic mechanisms in hypoxia | |||
| You Mie Lee (Kyungpook National University College of Pharmacy) | |||
| 4) SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin | |||
| Dong Hoon Shin (National Cancer Center) | |||
| Symposium 3 | 15:30~17:30, Room A | ||
| Joint Symposium (Korean Cancer Association & Korean Society of Pathologists) | |||
| Biobank, a hub of precision medicine | |||
| 1) Issues on sample acquisition for personalized cancer genome analysis | |||
| Woong-Yang Park (Sungkyunkwan University School of Medicine) | |||
| 2) Experience of Korean cancer biobank establishment | |||
| Do Youn Park (Pusan National University Medical School) | |||
| 3) International collaborative research involving Korea biobank: collaborative research experience in psoriasis and melanoma | |||
| Jaehwan Kim (The Rockefeller University, USA) | |||
| 4) Legal issues of human specimen research in Korea with a special reference to individual researcher | |||
| Baek-hui Kim (Korea University College of Medicine ) | |||
| Symposium 4 | 15:30~17:30, Room C | ||
| Druggable oncogenic pathway | |||
| 1) TBA | |||
| Premal Patel (Genentech, USA) | |||
| 2) Predicting and overcoming primary and acquired drug resistance | |||
| Luigi Manenti (Novartis, China) | |||
| 3) New trend in oncology drug development | |||
| Rafael Amado (GlaxoSmithKline, USA) | |||
| International Session | |||
| Basic 1, 2 | 13:20~15:10, Room B | ||
| Basic 3 | 14:10~15:10, Room D | ||
| Clinical 4, 5, 6 | 15:30~17:30, Room B | ||
| Clinical 7, 8 | 15:30~17:30, Room E | ||
| Oral Presentation | |||
| Breast cancer | 13:20~14:00, Room D | ||
| GI cancer 1, 2 | 13:20~15:10, Room E | ||
| Basic 1, 2 | 15:30~17:30, Room D | ||
| Luncheon Symposium 1 | 12:00~13:00, Room A ~ C | ||
| Personalized therapy in lung cancer | |||
| Kenneth O'Byrne (Princess Alexandra Hospital, Australia) | |||
| Poster | 09:00~17:00, Room F | ||